"The U.S. Food and Drug Administration today approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a previous heart "...
The adverse reactions which have occurred during treatment with Ancobon (flucytosine) are grouped according to organ system affected.
Gastrointestinal: Nausea, emesis, abdominal pain, diarrhea, anorexia, dry mouth, duodenal ulcer, gastrointestinal hemorrhage, acute hepatic injury with possible fatal outcome in debilitated patients, hepatic dysfunction, jaundice, ulcerative colitis, bilirubin elevation, increased hepatic enzymes.
Genitourinary: Azotemia, creatinine and BUN elevation, crystalluria, renal failure.
Read the Ancobon (flucytosine) Side Effects Center for a complete guide to possible side effects
Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of Ancobon (flucytosine) by competitive inhibition. Drugs which impair glomerular filtration may prolong the biological half-life of flucytosine.
Drug/Laboratory Test Interactions
Measurement of serum creatinine levels should be determined by the Jaffé reaction, since Ancobon (flucytosine) does not interfere with the determination of creatinine values by this method. Most automated equipment for measurement of creatinine makes use of the Jaffé reaction.
Read the Ancobon Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 10/8/2008
Additional Ancobon Information
Ancobon - User Reviews
Ancobon User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.